Continuous androgen deprivation may be a preferred treatment option for hormone-sensitive metastatic prostate cancer in men with minimal disease spread, according to results of a long-term international phase 3 trial reported at the 2012 Annual Meeting of the American Society of Clinical Oncology. Although some physicians recommend intermittent hormonal therapy to patients with metastatic prostate cancer, believing it will reduce risk of side effects without compromising outcomes, these findings demonstrate a clear downside to this approach for certain men, reported Maha Hussain, MD, of the University of Michigan, Ann Arbor, MI.
Physicians, nurse practitioners, physician assistants, nurses, and other healthcare providers who manage patients with prostate cancer.
After participating in this educational activity, participants should be better able to:
- Explain the role of androgen deprivation therapy (ADT) in the treatment of prostate cancer.
- Compare the efficacy and safety of intermittent ADT with that of continuous ADT therapy for men with hormone-sensitive metastatic prostate cancer.
Click Next to begin the activity.